Immune Design 10-Q 2 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 31, 2017
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	IMDZ
Entity Registrant Name	Immune Design Corp.
Entity Central Index Key	1,437,786
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		25,619,732

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 35,311	$ 45,214
Short-term investments	45,964	62,041
Accounts receivable	495	517
Inventory	624	607
Prepaid expenses	1,323	2,546
Restricted cash	6,000	0
Other receivables	123	3,156
Total current assets	89,840	114,081
Property and equipment, net	506	414
Other assets	525	0
Total assets	90,871	114,495
Current liabilities:
Accounts payable	4,246	4,559
Accrued liabilities	5,721	4,935
Accrued litigation-related settlement	7,250	7,250
Deferred revenue and other current liabilities	35	2,519
Total current liabilities	17,252	19,263
Other noncurrent liabilities	79	56
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized at June 30, 2017 (unaudited) and December 31, 2016; 25,590,065 and 25,413,055 shares issued and outstanding at June 30, 2017 (unaudited) and December 31, 2016, respectively	26	25
Additional paid-in capital	283,918	278,913
Accumulated deficit	(210,361)	(183,738)
Accumulated other comprehensive loss	(43)	(24)
Total stockholders’ equity	73,540	95,176
Total liabilities and stockholders’ equity	$ 90,871	$ 114,495

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Common stock
Par value per share (in dollars per share)	$ 0.001	$ 0.001
Shares authorized (in shares)	100,000,000	100,000,000
Shares issued (in shares)	25,590,065	25,413,055
Shares outstanding (in shares)	25,590,065	25,413,055
Preferred stock
Par value per share (in dollars per share)	$ 0.001	$ 0.001
Shares authorized (in shares)	10,000,000	10,000,000
Shares issued (in shares)	0	0
Shares outstanding (in shares)	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Product sales	$ 48	$ 733	$ 309	$ 740
Collaborative revenue	681	400	5,885	2,256
Total revenues	729	1,133	6,194	2,996
Operating expenses:
Cost of product sales	18	253	55	275
Research and development	10,863	11,386	24,901	21,956
General and administrative	3,888	3,948	8,023	7,862
Total operating expenses	14,769	15,587	32,979	30,093
Loss from operations	(14,040)	(14,454)	(26,785)	(27,097)
Interest and other income	194	107	319	456
Net loss	(13,846)	(14,347)	(26,466)	(26,641)
Unrealized gain (loss) on investments	4	10	(19)	30
Comprehensive loss	$ (13,842)	$ (14,337)	$ (26,485)	$ (26,611)
Basic and diluted net loss per share (in dollars per share)	$ (0.54)	$ (0.71)	$ (1.04)	$ (1.32)
Weighted-average shares used to compute basic and diluted net loss per share (in shares)	25,567,482	20,155,410	25,515,630	20,154,306

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities
Net loss	$ (26,466)	$ (26,641)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	169	151
Amortization of premium/discount on investments	56	(28)
Stock-based compensation expense	4,452	4,581
Changes in operating assets and liabilities:
Accounts receivable	22	595
Inventory	(17)	(711)
Prepaid expenses	1,223	(1,880)
Restricted cash	(6,000)	0
Other receivables	3,033	0
Other assets	(525)	0
Accounts payable	(313)	454
Accrued liabilities	786	3,142
Deferred revenue and other liabilities	(2,461)	(100)
Net cash used in operating activities	(26,041)	(20,437)
Investing activities
Purchases of property and equipment	(261)	(54)
Maturities of short-term investments	28,000	6,000
Purchases of short-term investments	(11,998)	(48,000)
Net cash provided by (used in) investing activities	15,741	(42,054)
Financing activities
Proceeds from issuances of common stock under equity incentive plans	397	101
Net cash provided by financing activities	397	101
Net decrease in cash and cash equivalents	(9,903)	(62,390)
Cash and cash equivalents, beginning of period	45,214	112,921
Cash and cash equivalents, end of period	$ 35,311	$ 50,531

Description of the Business

Description of the Business	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business Immune Design Corp. (we, us or our) is a clinical-stage immunotherapy company focused on cancer with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. We have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. We are developing multiple product candidates from our two discovery platforms, ZVex ® and GLAAS ® . Our primary product candidates, CMB305 and G100, utilize different immuno-oncology approaches and are in multiple Phase 1 and Phase 2 clinical trials. In addition, we have licensed to third parties the right to use the GLAAS platform in select infectious disease and allergy indications. We were incorporated in February 2008 in the State of Delaware. Our operations are headquartered in Seattle, Washington, and we have an additional facility in South San Francisco, California.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). To conform with GAAP, the preparation of our financial statements requires management to make judgments, assumptions, and estimates that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, accruals for clinical trial activity, other accrued liabilities, and assumptions used in determining stock-based compensation expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ materially from those estimates. Principles of Consolidation Our condensed consolidated financial statements include the financial position and results of operations of Immune Design Corp. and Immune Design Ltd., our wholly owned subsidiary. Immune Design Ltd. was incorporated in the United Kingdom in February 2016, and to date, there have been no financial transactions or balances related to this entity. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements as of June 30, 2017 and for the three and six months ended June 30, 2017 and 2016 and the related interim information contained within the notes to the condensed consolidated financial statements are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and in the opinion of management, reflect all normal recurring adjustments necessary for a fair statement of our financial position for the interim periods presented. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the year ended December 31, 2017 or for other future interim periods or years. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016 included in our Annual Report on Form 10-K for the year ended December 31, 2016 , filed with the Securities and Exchange Commission (SEC) on March 7, 2017 (Annual Report). Short-Term Investments Our short-term investments include funds invested in U.S. Treasury and agency securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized in interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive income (loss) using the specific-identification method. Restricted Cash Restricted cash includes funds used to secure our obligations associated with the settlement of all claims and disputes under the Settlement Agreement with TheraVectys SA (TVS). As of June 30, 2017 , a deposit of $6.0 million was held in escrow and restricted from withdrawal. See Note 11 for additional information. Comprehensive Loss Comprehensive loss is composed of net loss and other comprehensive income or loss that are excluded from net loss. For the periods presented, other comprehensive income consists of unrealized gains on our available-for-sale securities. Revenue Recognition We derive our revenue from collaboration and licensing agreements and the sale of products associated with material transfer, collaboration and supply agreements. Licensing fees are recognized when the amounts are earned and determinable during the applicable period. We recognize up-front nonrefundable license fees when due under contractual agreements and when we do not have a continuing obligation to provide services related to the agreement. Revenue associated with nonrefundable up-front license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected term of our continued involvement in the research and development process. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, we recognize such milestones as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable, (2) achievement of the milestone was not reasonably assured at the inception of the arrangement, (3) substantive effort is involved to achieve the milestone and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. Payments received in advance of work performed are recorded as unearned revenue. Certain agreements from which we derive our revenue include multiple deliverables. We recognize the revenue for each deliverable at fair value determined to be the estimated selling price in cases when neither vendor specific objective evidence nor third-party evidence is available. Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price to the customer is fixed or determinable and (4) collectability is reasonably assured. The evaluation of these revenue recognition criteria requires significant management judgment. For instance, we use judgment to assess collectability based on factors such as the customer’s creditworthiness and past collection history, if applicable. If we determine that collection of a payment is not reasonably assured, revenue recognition is deferred until receipt of payment. We also use judgment to assess whether a price is fixed or determinable including, but not limited to, reviewing contractual terms and conditions related to payment terms. Revenue from product sales of glucopyranosyl lipid A (GLA), a product from our GLAAS platforms, is recognized when the risk of loss has passed to the customer or deferred until such time that risk of loss has passed. All revenues associated from the sale of GLA products supplied by us are reported under product sales with the applicable costs reported under cost of product sales. Cost of product sales consist of the direct costs associated with the manufacture and formulation of GLA, including costs to purchase raw materials, third-party contract manufacturing costs, assay testing and ongoing product stability testing. Recently Adopted Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15 (Subtopic 205-40), Presentation of Financial Statements-Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (ASU 2014-15), which provides guidance about management’s responsibility to evaluate whether or not there is substantial doubt about the Company’s ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 was effective for fiscal years, and interim periods within those fiscal years, ending after December 15, 2016. We adopted this standard on January 1, 2017. In March 2016, the FASB issued ASU No. 2016-09-Improvements to Employee Share-Based Payment Accounting, which is intended to simplify several aspects of the accounting for share-based payment award transactions, including the income tax consequences, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. Under this guidance, on a prospective basis, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (APIC). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement. In addition, the guidance eliminates the requirement that excess tax benefits be realized before companies can recognize them. The ASU requires a cumulative-effect adjustment for previously unrecognized excess tax benefits in opening retained earnings in the annual period of adoption. As of January 1, 2017, we had an unrecognized excess tax benefit of $1.2 million . Upon adoption, we recognized this excess tax benefit as a deferred tax asset with a corresponding increase to our deferred tax asset valuation allowance. Additionally, as provided for under this new guidance, we elected to account for forfeitures as they occur. As of January 1, 2017, we had unrecorded forfeitures of $157,000 . Upon adoption, we recognized this expense as an adjustment to retained earnings with a corresponding increase to APIC. Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09 amending revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In August 2015, the FASB deferred the effective date of the revenue recognition guidance to reporting periods beginning after December 15, 2017. The new standard permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We currently anticipate adopting the new standard effective January 1, 2018, using the modified retrospective method. We will continue to monitor additional modifications, clarifications or interpretations undertaken by the FASB that may impact our current conclusions. We primarily derive our revenue from license and collaboration agreements. The consideration we are eligible to receive under these agreements includes upfront payments, research and development funding, milestone payments and royalties. Each license and collaboration agreement is unique and will be assessed separately under the five-step process under the new standard. The new revenue recognition standard differs from the current accounting standard in many respects, such as in the accounting for variable considerations and the measurement of progress toward completion of performance obligations. We have performed an initial review of all of our license and collaboration agreements and based upon our initial assessment, we do not currently anticipate a material impact on our financial position and results of operations. In February 2016, the FASB issued ASU 2016-02 related to lease accounting. This standard will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases that are greater than 12 months in duration. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases, however, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases will be recognized on the balance sheets. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest on the lease liability. For operating leases, lessees will recognize a single total lease expense. The standard is effective for public companies for the fiscal years and interim reporting periods beginning after December 15, 2018. We plan to adopt this new standard prospectively on January 1, 2019. We are evaluating the impact of the adoption of this standard on our unaudited condensed consolidated financial statements. We expect that it will increase our lease assets and correspondingly increase our lease liabilities. In August 2016, the FASB issued ASU No. 2016-15 which provides new guidance on the classification of certain cash receipts and payments in the statement of cash flows. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We will be required to adopt the new guidance beginning with the first fiscal quarter of 2018; early adoption is permitted. We are currently assessing the impact that the new guidance will have on our consolidated statements of cash flows. In November 2016, the FASB issued ASU No. 2016-18 that relates to restricted cash. The new guidance requires amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. We will be required to revise our consolidated statements of cash flows to adopt the new guidance beginning with the first fiscal quarter of 2018; early adoption is permitted. Adoption of the new guidance will not have a significant impact on our financial position and results of operations. In May 2017, the FASB issued ASU No. 2017-09 to provide clarity and reduce both diversity in practice and cost and complexity when applying the guidance in Topic 718 about a change to the terms and conditions of a share-based payment award. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this update are effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, and applied prospectively to modifications that occur on or after the adoption date. We are currently reviewing and evaluating this recent update and plan to adopt on the required adoption date. For the quarter ended June 30, 2017, there were no modifications to the terms or conditions of a share-based payment award.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Because of net losses recognized in each period, potential shares of common stock issuable upon the exercise of outstanding stock options have not been reflected in the calculation of diluted net loss per share due to the anti-dilutive effect. Diluted net loss per share, therefore, does not differ from basic net loss per share. The common stock equivalents issuable upon the exercise of the following dilutive securities have been excluded from the computation of diluted net loss per share attributable to common stockholders calculation because their effect would have been anti-dilutive for the periods presented: June 30, 2017 2016 (unaudited) Outstanding options to purchase common stock 4,142,900 3,493,863 Unvested restricted stock units 297,025 115,250 Total outstanding shares of common stock equivalents 4,439,925 3,609,113

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Investments	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Cash Equivalents and Short-Term Investments	Cash Equivalents and Short-Term Investments The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands): June 30, 2017 (unaudited) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Money market funds $ 23,767 $ — $ — $ 23,767 U.S. agency securities 6,000 — — 6,000 U.S. Treasury securities 49,007 — (43 ) 48,964 Total $ 78,774 $ — $ (43 ) $ 78,731 Classified as: Cash equivalents $ 32,767 Short-term investments 45,964 Total $ 78,731 All U.S. Treasury and agency securities held as of June 30, 2017 were classified as available-for-sale securities and had contractual maturities of less than one year. There were no realized gains or losses on these securities for the period presented.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments We measure and record cash and cash equivalents and short-term investments at fair value in the accompanying condensed consolidated financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows: Level 1 : Quoted prices in active markets for identical assets or liabilities. Level 2 : Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 : Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 1 securities consist of highly liquid money market funds and U.S. Treasury securities. The fair value of Level 1 assets has been determined using quoted prices in active markets for identical assets. The following table summarizes our financial assets measured at fair value on a recurring basis (in thousands): June 30, 2017 (unaudited) Assets: LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Money market funds $ 23,767 $ — $ — $ 23,767 U.S. agency securities — 6,000 — 6,000 U.S. treasury securities 48,964 — — 48,964 Total $ 72,731 $ 6,000 $ — $ 78,731 December 31, 2016 Assets: LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Money market funds $ 36,414 $ — $ — $ 36,414 U.S. treasury securities 62,040 — — 62,040 Total $ 98,454 $ — $ — $ 98,454

Inventory

Inventory	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following (in thousands): June 30, December 31, (unaudited) Raw materials $ — $ 567 Work in process 541 — Finished goods 83 40 Total inventory $ 624 $ 607

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following (in thousands): June 30, December 31, (unaudited) Research and development services $ 4,179 $ 3,027 Legal and professional services 136 28 Employee compensation 1,406 1,880 Total accrued liabilities $ 5,721 $ 4,935

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases We lease laboratory and office space under an operating lease in Seattle, Washington. Our previous lease commenced in February 2013 and ended December 2016. In January 2016, we entered into a new Lease Agreement for approximately 20,133 square feet of office and laboratory space, which includes and expands on the space we previously subleased for our headquarters. The lease commenced on January 1, 2017 and has a term of five years with an option to extend the lease term by three years. The annual base rent due under the lease is $1.1 million for the first year and will increase by 2.5% each year thereafter. Under the terms of this lease agreement, we provided a $200,000 security deposit in January 2017. In May 2017 , we entered into a sublease agreement with a third party subtenant. As sublandlord under this agreement, we are subleasing 5,048 square feet of the Seattle laboratory and office space for a period of three years. The annual base rent payable under this sublease is $273,000 for the first year and will increase by 2.5% each year thereafter. Rent under this sublease agreement is reflected in other income. We also lease 9,640 square feet of office space under an operating lease in South San Francisco, California. The lease commenced in January 2015 and continues through January 2020, with an option to extend for an additional five years . In connection with the lease, we were required to provide a $121,000 letter of credit as a security deposit. As of June 30, 2017 , no funds had been drawn on the letter of credit. Contingencies In June 2015, we entered into a clinical supply agreement with NanoPass Technologies LTD (NanoPass) for the use of its intradermal delivery device in certain of our clinical trials. In July 2015, in connection with the execution of the agreement, we paid an upfront fee of $600,000 for access and rights to use this device. In December 2015, we initiated our Phase 2 clinical trial of CMB305 in patients with soft tissue sarcoma, which triggered a milestone payment of $500,000 . Both the upfront fee and milestone payments were capitalized to prepaid expenses on the accompanying condensed consolidated balance sheets and are being amortized to research and development expense over the related milestone periods. We amortized to research and development expense $0 and $261,000 during the three months ended June 30, 2017 and 2016 , respectively, and $0 and $522,000 for the six months ended June 30, 2017 and 2016 , respectively. As of June 30, 2017 , the upfront and milestone payments have been fully amortized to research and development expense. In October 2016, we entered into a letter agreement with NanoPass, which amended our clinical supply agreement to expand the field of use to include all oncology immunotherapy applications and include additional milestone payments that would be paid to NanoPass upon achievement of certain clinical milestones. Per the terms of the letter agreement, we paid NanoPass an additional upfront, one-time, non-refundable payment of $150,000 . In addition, we agreed to pay certain future milestone fees up to an aggregate of $8.8 million upon the achievement of certain clinical milestones using this device. Under our license agreements with the Infectious Disease Research Institute (IDRI), we are contingently obligated to pay potential future milestone payments for products developed from our GLAAS platform, which could total up to $2.3 million and $1.3 million , respectively, for the first and each subsequent exclusive licensed product we develop, and $1.3 million and $625,000 , respectively, for the first and each subsequent non-exclusive licensed product we develop. We are contingently obligated to pay potential future milestone payments to third parties as part of certain licensing agreements for the ZVex products we develop, which could total up to $7.7 million in aggregate payments. These payments generally become due and payable only upon achievement of certain clinical development, regulatory or commercial milestones. We also have potential future royalty payments we may be required to make under our licensing agreements as described in Note 9. Payments under these agreements are uncertain due to the occurrence of the events requiring payment under these agreements, including our share of potential future milestone and royalty payments and the likelihood and timing of obtaining regulatory approval for the commercial sale of our products.

License and Collaboration Agree

License and Collaboration Agreements	6 Months Ended
	Jun. 30, 2017
Research and Development [Abstract]
License and Collaboration Agreements	License and Collaboration Agreements Licenses Granted In August 2014, we entered into an agreement with Sanofi under which we granted Sanofi an exclusive license for the use of our GLAAS platform to discover, develop and commercialize products to treat peanut allergy. We recognized no milestone revenue under this agreement for the three and six months ended June 30, 2017 and 2016 , respectively. The agreement provides for additional potential payments of up to $160.0 million based upon the attainment of certain development and commercialization milestones and tiered royalties on sales of approved products. Sanofi may terminate the agreement at any time upon six months’ written notice. We currently have two separate license agreements with MedImmune, LLC (MedImmune), entered into in October 2010, pursuant to which we granted MedImmune a worldwide, sublicensable, exclusive license to use GLA to develop and sell vaccines in two different infectious disease indications. Under the license agreements, MedImmune is obligated to use commercially reasonable efforts to develop and obtain regulatory approval for a licensed product in certain markets and to market and sell licensed products in any country where it obtains regulatory approval. In 2010, MedImmune paid us upfront payments under the license agreements. Under each license agreement, MedImmune is obligated to make additional payments based on achievement of certain development, regulatory, and commercial milestones for the licensed indication. MedImmune is also obligated to pay us a low double-digit percentage share of non-royalty payments that it receives from sublicensees and a mid single-digit percentage royalty payment on net sales of licensed products, which royalty is subject to reduction under certain circumstances. Under each license agreement, MedImmune is obligated to make additional aggregate payments of up to $62.9 million to $72.5 million , depending on the infectious disease indication and the achievement of certain development, regulatory and commercial milestones for the licensed indication. We recognized no revenue for the achievement of development milestones under these license agreements for the three and six months ended June 30, 2017 and 2016 , respectively. In May 2013, we entered into a nonexclusive license agreement granting Medicago, Inc. (Medicago) a right to research, develop, and commercialize GLA in the field of pandemic influenza. In 2013, Medicago paid an upfront payment of $500,000 under the license agreement, and Medicago is obligated to make additional payments of up to $9.5 million based on the achievement of certain development and government contract milestones for the licensed indication. Medicago is also obligated to pay us a mid single-digit royalty on net sales of licensed products, which royalty is subject to reduction under license expiration. No revenue was recognized under the agreement for the three and six months ended June 30, 2017 and 2016 , respectively. Licenses Acquired In July 2008, we licensed certain patent rights, know-how and technology related to our GLAAS platform from IDRI, specifically products and formulations containing GLA and another synthetic TLR4 agonist referred to as SLA. This license was first amended and restated in 2010. In November 2015, we entered into a separate agreement with IDRI to license a patent related to our GLAAS technology in the field of cancer. Under this agreement, we paid IDRI an upfront license fee in the amount of $250,000 , which was recognized as research and development expense. Upon the achievement of certain developmental and regulatory milestones, we will be obligated to pay IDRI up to $250,000 and $125,000 , respectively, for the first and each subsequent licensed product we develop. In December 2015, we entered into a Second Amended and Restated License Agreement with IDRI, in which we obtained additional rights under the licensed technology, which rights vary by disease indication, and we returned to IDRI certain previously licensed GLA rights in select, primarily developing-world infectious disease indications. We received an exclusive license for SLA products in oncology, human allergy and addiction, as well as an option to obtain additional exclusive licenses in select infectious disease indications. In December 2015, in connection with the execution of the second restated agreement, we paid an upfront fee of $2.3 million , which was recorded as research and development expense. We are obligated to pay IDRI up to $2.3 million and $1.3 million , respectively, in additional payments for the first and each subsequent exclusive licensed product we develop, and $1.3 million and $625,000 , respectively, for the first and each subsequent non-exclusive licensed product we develop, based on the achievement of certain developmental and regulatory milestones. In addition, we will be obligated to pay certain commercialization milestones and royalty payments as a single-digit percentage of net sales, if and when a licensed product is commercialized. We are also obligated to share with IDRI a percentage of payments received from any third-party sublicensees. Additionally, if we exercise our option for additional infectious disease indications, we will be required to make upfront, milestone and royalty payments for such additional indications, which payments are subject to similar terms and conditions as are applicable to other milestone and royalty payments. We recognized no IDRI license-related milestone fees for the three and six months ended June 30, 2017 and 2016 . In 2009, we licensed certain patent rights utilized in our ZVex development platform from the California Institute of Technology (Caltech). As part of acquiring this license, we issued shares of our common stock valued at $25,000 . We make annual minimum royalty payments of $25,000 under the license. In addition, we are obligated to pay Caltech up to an aggregate of $1.5 million in additional payments upon the achievement of certain development and regulatory milestones and will owe royalty payments on net sales of licensed products in the low single-digit percentage, if and when commercialized. We recognized $100,000 in Caltech milestone fees for the three and six months ended June 30, 2017 , and recognized no Caltech milestone fees for the three and six months ended June 30, 2016 . In June 2015, we entered into a clinical supply agreement with NanoPass for the use of their intradermal delivery device in certain of our clinical trials. See Note 8 for additional information. In October 2016, we entered into a license agreement with TheraVectys SA (TVS), pursuant to which we received a field limited, non-exclusive, sublicensable license in the field of oncology to certain current and future intellectual property rights owned, controlled and licensed by TVS relating to lentiviral vector technologies. We will owe TVS milestone payments based on the achievement of certain development and regulatory milestones for each licensed product, in the aggregate amount of up to $5.75 million , except that the first two milestones payments are waived for CMB305/LV305. In addition, we will be obligated to pay a single commercial milestone payment for each product that achieves a specified net sales amount. We will owe royalties to TVS on product sales that are made directly by us or our affiliates, subject to certain royalty-offset provisions. For the first four products, royalties will be based on a low-single digit percentage of net sales, and for subsequent products, tiered royalties will be based on low-to-mid-single digit percentages of net sales. TVS will also receive a mid-single digit percentage of revenues that we receive for sublicensing the licensed intellectual property. We recognized no TVS milestone fees for the three and six months ended June 30, 2017 and 2016 . Collaborations In October 2014, we entered into a collaboration with Sanofi Pasteur for the development of a Herpes Simplex Virus (HSV) immune therapy. Sanofi Pasteur and Immune Design are each contributing product candidates to the collaboration: Sanofi Pasteur is contributing HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, and we are contributing G103, our preclinical trivalent vaccine product candidate. The collaboration will explore the potential of various combinations of agents, including leveraging our GLAAS platform, with the goal to select the best potential immune therapy for patients. Each company will develop the products jointly through Phase 2 clinical trials, at which point Sanofi Pasteur intends to continue development of the most promising candidate and be responsible for commercialization. Sanofi Pasteur will bear the costs of all preclinical and clinical development, with Immune Design providing a specific formulation of GLA from the GLAAS platform at its cost through Phase 2 studies. Immune Design will be eligible to receive future milestone and royalty payments on any licensed product developed from the collaboration. We recognize funding from collaborative research and development efforts as revenue as we perform or deliver the related services in accordance with contract terms as long as we will receive payment for such services upon standard payment terms. The costs of the related services performed are recorded as research and development expenses on the condensed consolidated statements of operations and comprehensive loss. Under this collaboration we recognized revenue of $700,000 and $400,000 for the three months ended June 30, 2017 and 2016 , respectively, and $5.9 million and $2.3 million for the six months ended June 30, 2017 and 2016 , respectively. As of June 30, 2017 , we have a receivable of $428,000 due from Sanofi Pasteur on our accompanying condensed consolidated balance sheets related to this agreement.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock Our board of directors has the authority to fix and determine and to amend the number of shares of any series of preferred stock that is wholly unissued or to be established and to fix and determine and to amend the designation, preferences, voting powers and limitations, and the relative, participating, optional or other rights, of any series of shares of preferred stock that is wholly unissued or to be established. There was no preferred stock issued and outstanding as of June 30, 2017 or December 31, 2016 . Common Stock We had 25,590,065 and 25,413,055 shares of common stock outstanding as of June 30, 2017 and December 31, 2016 , respectively. Shares of common stock reserved for future issuance were as follows: June 30, December 31, (unaudited) Shares available for issuance under the employee stock purchase plan 484,822 503,620 Options granted and outstanding 4,142,900 3,590,393 Unvested restricted stock units 297,025 107,250 Shares available for future stock option grants 840,751 724,723 Shares of common stock reserved for future issuance 5,765,498 4,925,986 Equity Incentive Plans Under our 2014 Omnibus Incentive Plan (2014 Plan), the total number of shares of common stock available for issuance increase annually on January 1 of each year in an amount equal to 4% of the total number of shares of our common stock issued and outstanding as of December 31 of the immediately preceding year, or such lesser amount as deemed appropriate by our Board of Directors. On January 1, 2017, the authorized shares available under the 2014 Plan were increased by 1,016,522 shares. There were a total of 3,953,577 shares of common stock authorized under the 2014 Plan as of June 30, 2017 . Under our 2014 Employee Stock Purchase Plan (2014 ESPP), the total number of shares of common stock available for issuance increase annually on January 1 of each year in an amount equal to the lesser of (i) 1% of the total number of shares issued and outstanding as of December 31 of the immediately preceding year, (ii) 200,000 shares, or such lesser amount as deemed appropriate by our Board of Directors. For 2017, the Board of Directors determined the current shares available for issuance under the 2014 ESPP were sufficient and did not increase the amount of authorized shares. There were a total of 484,822 shares of common stock authorized under the 2014 ESPP as of June 30, 2017 . Restricted Stock Units Summary restricted stock units (RSUs) information is as follows: SHARES WEIGHTED AVERAGE GRANT DATE FAIR VALUE (per share) Outstanding at December 31, 2016 107,250 $ 19.39 Granted (unaudited) 224,540 5.60 Vested (unaudited) (26,802 ) 19.39 Forfeited (unaudited) (7,963 ) 11.12 Outstanding at June 30, 2017 (unaudited) 297,025 9.19 Stock Option Activity Summary stock option information is as follows: OPTIONS OUTSTANDING WEIGHTED- AVERAGE EXERCISE PRICE WEIGHTED- AVERAGE REMAINING CONTRACT TERM (in years) AGGREGATE INTRINSIC VALUE (in thousands) Outstanding at December 31, 2016 3,590,393 $ 12.13 7.33 Granted (unaudited) 819,801 $ 5.93 Exercised (unaudited) (131,410 ) $ 1.24 Expired (unaudited) (48,478 ) $ 18.82 Forfeited (unaudited) (87,406 ) $ 14.13 Outstanding at June 30, 2017 (unaudited) 4,142,900 $ 11.13 7.56 $ 13,063 Exercisable as of June 30, 2017 (unaudited) 2,168,589 $ 10.63 6.42 $ 8,829 As of June 30, 2017 , there was $14.2 million of total unrecognized stock-based compensation expense related to nonvested stock options that is expected to be recognized over a weighted-average period of 2.3 years . The total intrinsic value of options exercised during the six months ended June 30, 2017 and 2016 was $639,000 and $34,000 , respectively. Stock-Based Compensation Expense Prior to the adoption of ASU No. 2016-09 on January 1, 2017, employee stock-based compensation expense recognized was calculated based on awards ultimately expected to vest and was reduced for estimated forfeitures. Effective January 1, 2017, upon our adoption of ASU No. 2016-09, we have elected to account for forfeitures as they occur. Total stock-based compensation expense recognized in our condensed consolidated statements of operations and comprehensive income (loss) is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) Employee: Research and development $ 904 $ 927 $ 1,837 $ 1,936 General and administrative 1,242 1,258 2,522 2,555 Non-Employee: Research and development 34 35 57 37 General and administrative 25 26 36 53 Total stock-based compensation expense $ 2,205 $ 2,246 $ 4,452 $ 4,581 We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The fair values of stock options granted to employees were calculated using the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) Weighted-average estimated fair value $4.86 $8.64 $3.93 $12.48 Risk-free interest rate 1.86% - 1.98% 1.19% - 1.49% 1.86% - 2.09% 1.19% - 1.84% Expected term of options (in years) 6.08 5.85 - 6.08 5.50 - 6.08 5.50 - 6.08 Expected stock price volatility 80% 78% - 80% 80% - 82% 77% - 80% Expected dividend yield — — — —

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2017
Loss Contingency [Abstract]
Legal Proceedings	Legal Proceedings Settlement and License Agreements with TheraVectys SA On October 17, 2016, we entered into a Settlement Agreement and a License Agreement with TheraVectys SA (TVS) obtaining certain present and future intellectual property rights and resolving the litigation that TVS initiated against us in the Chancery Court of the State of Delaware in July 2014, as well as related claims and counterclaims. Please see our prior periodic reports filed with the U.S. Securities and Exchange Commission for a detailed summary of the proceedings. Under the Settlement Agreement, TVS agreed to dismiss all pending litigation brought by TVS against us and to withdraw patent opposition proceedings (EPO Proceeding) brought by TVS against our European Patent No EP 2 456 786 (EU Patent). Also under the Settlement Agreement, both parties agreed to a broad release of claims against one another based on acts or omissions arising out of the litigation, or the facts and circumstances giving rise to the litigation. Neither party made any admission of liability or wrongdoing under the Settlement Agreement. As a non-contingent fee for a license to certain present and future intellectual property of TVS, and in consideration for the settlement of all claims and disputes between the parties, we have paid $6.0 million into an escrow account (Escrowed Payment), and we have also agreed to pay $1.25 million to TVS when we next raise $25.0 million , in the aggregate, through equity sales, debt or licensing revenue. The Escrowed Payment will be disbursed to TVS as follows: (a) fifty percent ( 50% ) when (i) Institut Pasteur consents to the granting by TVS to us of a sublicense to certain patents licensed by TVS (or to be licensed by TVS) from Institut Pasteur and (ii) the litigation in the United States and Belgium has been dismissed and resolved; and (b) fifty percent ( 50% ) upon the final resolution of the EPO Proceeding if the scope of the EU Patent remains unchanged (Escrow Conditions); provided, that the events described in item (a) are a condition to the release of any portion of the Escrowed Payment to TVS, and delays in satisfying the Escrow Conditions may potentially result in a reduction of the amount of the Escrowed Payment that is disbursed to TVS. We believe the Escrow Conditions have been recently satisfied and are in discussions with TVS on the disbursement of the Escrow Payment. As of June 30, 2017 , none of the Escrowed Payment has been disbursed. We determined that the aggregate payment amount expected to be paid to TVS is $7.25 million and as such, the aggregate payment amount should be allocated between (1) dismissal of the litigation; and (2) license to current and future TVS intellectual property (IP). As we are not able to reliably estimate the fair value of the litigation dismissal, we assigned a fair value to the aggregate amount of the license to current and future TVS IP through the use of a benchmarking approach and determined the fair value of the license to current and future IP obtained from TVS by benchmarking this deal against similar recent (within the last 5 years) deals within our industry. The metrics we used in our benchmarking approach included similarities in industry, product type, therapeutic area, stage of product development and exclusivity. Based upon the results of our benchmark approach, we determined that the fair value assigned to the license to current and future TVS IP to be $1.4 million with the remaining residual amount of $5.85 million allocated to the dismissal of the litigation. For the year ended December 31, 2016, the $5.85 million allocated to the dismissal of litigation is recorded as a general and administrative expense and the $1.4 million allocated to the license acquired for current and future TVS IP granted to us is recorded as a research and development expense on the condensed consolidated statements of operations and comprehensive income (loss).

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On July 3, 2017, we entered into a Sales Agreement (ATM Agreement) with Cowen and Company, LLC (Cowen) under which we may offer and sell, from time to time at our sole discretion through Cowen, as our sales agent, shares of our common stock having an aggregate offering price of up to $50.0 million . Cowen may sell the common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including sales made directly on or through the NASDAQ Global Market or on any other existing trading market for our common stock. Any common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-206324). We will pay Cowen a commission equal to 3.0% of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement and also have provided Cowen with indemnification and contribution rights. To date, we have not sold any common stock under the ATM Agreement.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). To conform with GAAP, the preparation of our financial statements requires management to make judgments, assumptions, and estimates that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, accruals for clinical trial activity, other accrued liabilities, and assumptions used in determining stock-based compensation expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ materially from those estimates.
Principles of Consolidation	Principles of Consolidation Our condensed consolidated financial statements include the financial position and results of operations of Immune Design Corp. and Immune Design Ltd., our wholly owned subsidiary. Immune Design Ltd. was incorporated in the United Kingdom in February 2016, and to date, there have been no financial transactions or balances related to this entity.
Short-Term Investments	Short-Term Investments Our short-term investments include funds invested in U.S. Treasury and agency securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized in interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive income (loss) using the specific-identification method.
Restricted Cash	Restricted Cash Restricted cash includes funds used to secure our obligations associated with the settlement of all claims and disputes under the Settlement Agreement with TheraVectys SA (TVS).
Comprehensive Loss	Comprehensive Loss Comprehensive loss is composed of net loss and other comprehensive income or loss that are excluded from net loss. For the periods presented, other comprehensive income consists of unrealized gains on our available-for-sale securities.
Revenue Recognition	Revenue Recognition We derive our revenue from collaboration and licensing agreements and the sale of products associated with material transfer, collaboration and supply agreements. Licensing fees are recognized when the amounts are earned and determinable during the applicable period. We recognize up-front nonrefundable license fees when due under contractual agreements and when we do not have a continuing obligation to provide services related to the agreement. Revenue associated with nonrefundable up-front license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected term of our continued involvement in the research and development process. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, we recognize such milestones as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable, (2) achievement of the milestone was not reasonably assured at the inception of the arrangement, (3) substantive effort is involved to achieve the milestone and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. Payments received in advance of work performed are recorded as unearned revenue. Certain agreements from which we derive our revenue include multiple deliverables. We recognize the revenue for each deliverable at fair value determined to be the estimated selling price in cases when neither vendor specific objective evidence nor third-party evidence is available. Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price to the customer is fixed or determinable and (4) collectability is reasonably assured. The evaluation of these revenue recognition criteria requires significant management judgment. For instance, we use judgment to assess collectability based on factors such as the customer’s creditworthiness and past collection history, if applicable. If we determine that collection of a payment is not reasonably assured, revenue recognition is deferred until receipt of payment. We also use judgment to assess whether a price is fixed or determinable including, but not limited to, reviewing contractual terms and conditions related to payment terms. Revenue from product sales of glucopyranosyl lipid A (GLA), a product from our GLAAS platforms, is recognized when the risk of loss has passed to the customer or deferred until such time that risk of loss has passed. All revenues associated from the sale of GLA products supplied by us are reported under product sales with the applicable costs reported under cost of product sales. Cost of product sales consist of the direct costs associated with the manufacture and formulation of GLA, including costs to purchase raw materials, third-party contract manufacturing costs, assay testing and ongoing product stability testing.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15 (Subtopic 205-40), Presentation of Financial Statements-Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (ASU 2014-15), which provides guidance about management’s responsibility to evaluate whether or not there is substantial doubt about the Company’s ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 was effective for fiscal years, and interim periods within those fiscal years, ending after December 15, 2016. We adopted this standard on January 1, 2017. In March 2016, the FASB issued ASU No. 2016-09-Improvements to Employee Share-Based Payment Accounting, which is intended to simplify several aspects of the accounting for share-based payment award transactions, including the income tax consequences, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. Under this guidance, on a prospective basis, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (APIC). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement. In addition, the guidance eliminates the requirement that excess tax benefits be realized before companies can recognize them. The ASU requires a cumulative-effect adjustment for previously unrecognized excess tax benefits in opening retained earnings in the annual period of adoption. As of January 1, 2017, we had an unrecognized excess tax benefit of $1.2 million . Upon adoption, we recognized this excess tax benefit as a deferred tax asset with a corresponding increase to our deferred tax asset valuation allowance. Additionally, as provided for under this new guidance, we elected to account for forfeitures as they occur. As of January 1, 2017, we had unrecorded forfeitures of $157,000 . Upon adoption, we recognized this expense as an adjustment to retained earnings with a corresponding increase to APIC. Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09 amending revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In August 2015, the FASB deferred the effective date of the revenue recognition guidance to reporting periods beginning after December 15, 2017. The new standard permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We currently anticipate adopting the new standard effective January 1, 2018, using the modified retrospective method. We will continue to monitor additional modifications, clarifications or interpretations undertaken by the FASB that may impact our current conclusions. We primarily derive our revenue from license and collaboration agreements. The consideration we are eligible to receive under these agreements includes upfront payments, research and development funding, milestone payments and royalties. Each license and collaboration agreement is unique and will be assessed separately under the five-step process under the new standard. The new revenue recognition standard differs from the current accounting standard in many respects, such as in the accounting for variable considerations and the measurement of progress toward completion of performance obligations. We have performed an initial review of all of our license and collaboration agreements and based upon our initial assessment, we do not currently anticipate a material impact on our financial position and results of operations. In February 2016, the FASB issued ASU 2016-02 related to lease accounting. This standard will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases that are greater than 12 months in duration. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases, however, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases will be recognized on the balance sheets. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest on the lease liability. For operating leases, lessees will recognize a single total lease expense. The standard is effective for public companies for the fiscal years and interim reporting periods beginning after December 15, 2018. We plan to adopt this new standard prospectively on January 1, 2019. We are evaluating the impact of the adoption of this standard on our unaudited condensed consolidated financial statements. We expect that it will increase our lease assets and correspondingly increase our lease liabilities. In August 2016, the FASB issued ASU No. 2016-15 which provides new guidance on the classification of certain cash receipts and payments in the statement of cash flows. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We will be required to adopt the new guidance beginning with the first fiscal quarter of 2018; early adoption is permitted. We are currently assessing the impact that the new guidance will have on our consolidated statements of cash flows. In November 2016, the FASB issued ASU No. 2016-18 that relates to restricted cash. The new guidance requires amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. We will be required to revise our consolidated statements of cash flows to adopt the new guidance beginning with the first fiscal quarter of 2018; early adoption is permitted. Adoption of the new guidance will not have a significant impact on our financial position and results of operations. In May 2017, the FASB issued ASU No. 2017-09 to provide clarity and reduce both diversity in practice and cost and complexity when applying the guidance in Topic 718 about a change to the terms and conditions of a share-based payment award. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this update are effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, and applied prospectively to modifications that occur on or after the adoption date. We are currently reviewing and evaluating this recent update and plan to adopt on the required adoption date. For the quarter ended June 30, 2017, there were no modifications to the terms or conditions of a share-based payment award.
Net Loss Per Share	Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Because of net losses recognized in each period, potential shares of common stock issuable upon the exercise of outstanding stock options have not been reflected in the calculation of diluted net loss per share due to the anti-dilutive effect. Diluted net loss per share, therefore, does not differ from basic net loss per share.
Fair Value Measurement	We measure and record cash and cash equivalents and short-term investments at fair value in the accompanying condensed consolidated financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows: Level 1 : Quoted prices in active markets for identical assets or liabilities. Level 2 : Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 : Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 1 securities consist of highly liquid money market funds and U.S. Treasury securities. The fair value of Level 1 assets has been determined using quoted prices in active markets for identical assets.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Common Stock Issuable Upon the Conversion or Exercise of Dilutive Securities Excluded from Diluted Net Loss Per Share Attributable to Common Stockholders	The common stock equivalents issuable upon the exercise of the following dilutive securities have been excluded from the computation of diluted net loss per share attributable to common stockholders calculation because their effect would have been anti-dilutive for the periods presented: June 30, 2017 2016 (unaudited) Outstanding options to purchase common stock 4,142,900 3,493,863 Unvested restricted stock units 297,025 115,250 Total outstanding shares of common stock equivalents 4,439,925 3,609,113

Cash Equivalents and Short-Te20

Cash Equivalents and Short-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Cash and Cash Equivalents and Short-term Investments	The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands): June 30, 2017 (unaudited) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Money market funds $ 23,767 $ — $ — $ 23,767 U.S. agency securities 6,000 — — 6,000 U.S. Treasury securities 49,007 — (43 ) 48,964 Total $ 78,774 $ — $ (43 ) $ 78,731 Classified as: Cash equivalents $ 32,767 Short-term investments 45,964 Total $ 78,731

Fair Value of Financial Instr21

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Financial Assets Measured at Fair Value on a Recurring Basis	The following table summarizes our financial assets measured at fair value on a recurring basis (in thousands): June 30, 2017 (unaudited) Assets: LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Money market funds $ 23,767 $ — $ — $ 23,767 U.S. agency securities — 6,000 — 6,000 U.S. treasury securities 48,964 — — 48,964 Total $ 72,731 $ 6,000 $ — $ 78,731 December 31, 2016 Assets: LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Money market funds $ 36,414 $ — $ — $ 36,414 U.S. treasury securities 62,040 — — 62,040 Total $ 98,454 $ — $ — $ 98,454

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventory	Inventory consists of the following (in thousands): June 30, December 31, (unaudited) Raw materials $ — $ 567 Work in process 541 — Finished goods 83 40 Total inventory $ 624 $ 607

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): June 30, December 31, (unaudited) Research and development services $ 4,179 $ 3,027 Legal and professional services 136 28 Employee compensation 1,406 1,880 Total accrued liabilities $ 5,721 $ 4,935

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Schedule of Shares of Common Stock Reserved for Future Issuance	Shares of common stock reserved for future issuance were as follows: June 30, December 31, (unaudited) Shares available for issuance under the employee stock purchase plan 484,822 503,620 Options granted and outstanding 4,142,900 3,590,393 Unvested restricted stock units 297,025 107,250 Shares available for future stock option grants 840,751 724,723 Shares of common stock reserved for future issuance 5,765,498 4,925,986
Schedule of Restricted Stock Unit Activity	Summary restricted stock units (RSUs) information is as follows: SHARES WEIGHTED AVERAGE GRANT DATE FAIR VALUE (per share) Outstanding at December 31, 2016 107,250 $ 19.39 Granted (unaudited) 224,540 5.60 Vested (unaudited) (26,802 ) 19.39 Forfeited (unaudited) (7,963 ) 11.12 Outstanding at June 30, 2017 (unaudited) 297,025 9.19
Summary of Stock Options	Summary stock option information is as follows: OPTIONS OUTSTANDING WEIGHTED- AVERAGE EXERCISE PRICE WEIGHTED- AVERAGE REMAINING CONTRACT TERM (in years) AGGREGATE INTRINSIC VALUE (in thousands) Outstanding at December 31, 2016 3,590,393 $ 12.13 7.33 Granted (unaudited) 819,801 $ 5.93 Exercised (unaudited) (131,410 ) $ 1.24 Expired (unaudited) (48,478 ) $ 18.82 Forfeited (unaudited) (87,406 ) $ 14.13 Outstanding at June 30, 2017 (unaudited) 4,142,900 $ 11.13 7.56 $ 13,063 Exercisable as of June 30, 2017 (unaudited) 2,168,589 $ 10.63 6.42 $ 8,829
Schedule of Stock-Based Compensation Expense Recognized	Total stock-based compensation expense recognized in our condensed consolidated statements of operations and comprehensive income (loss) is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) Employee: Research and development $ 904 $ 927 $ 1,837 $ 1,936 General and administrative 1,242 1,258 2,522 2,555 Non-Employee: Research and development 34 35 57 37 General and administrative 25 26 36 53 Total stock-based compensation expense $ 2,205 $ 2,246 $ 4,452 $ 4,581
Schedule of Fair Value of Stock Options Granted to Employees	The fair values of stock options granted to employees were calculated using the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) Weighted-average estimated fair value $4.86 $8.64 $3.93 $12.48 Risk-free interest rate 1.86% - 1.98% 1.19% - 1.49% 1.86% - 2.09% 1.19% - 1.84% Expected term of options (in years) 6.08 5.85 - 6.08 5.50 - 6.08 5.50 - 6.08 Expected stock price volatility 80% 78% - 80% 80% - 82% 77% - 80% Expected dividend yield — — — —

Description of the Business - N

Description of the Business - Narrative (Details)	6 Months Ended
	Jun. 30, 2017platform
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of discovery platforms (in platforms)	2

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jan. 01, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Restricted cash	$ 6,000		$ 0
Unrecognized Tax Benefits		$ 1,200
Additional Paid-in Capital | Accounting Standards Update 2016-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Adjustment to retained earnings and APIC resulting from adoption of new accounting pronouncement		157
Retained Earnings | Accounting Standards Update 2016-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Adjustment to retained earnings and APIC resulting from adoption of new accounting pronouncement		$ (157)

Net Loss Per Share - Common Sto

Net Loss Per Share - Common Stock Issuable Upon the Conversion or Exercise of Dilutive Securities Excluded from Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,439,925	3,609,113
Outstanding options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,142,900	3,493,863
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	297,025	115,250

Cash Equivalents and Short-Te28

Cash Equivalents and Short-Term Investments (Details)	6 Months Ended
	Jun. 30, 2017USD ($)
Gain (Loss) on Investments [Line Items]
Amortized Cost	$ 78,774,000
Gross Unrealized Gains	0
Gross Unrealized Losses	(43,000)
Fair Value	78,731,000
Cash equivalents	32,767,000
Short-term investments	45,964,000
Total	78,731,000
Money market funds
Gain (Loss) on Investments [Line Items]
Amortized Cost	23,767,000
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	23,767,000
U.S. agency securities
Gain (Loss) on Investments [Line Items]
Amortized Cost	6,000,000
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	6,000,000
U.S. Treasury securities
Gain (Loss) on Investments [Line Items]
Amortized Cost	49,007,000
Gross Unrealized Gains	0
Gross Unrealized Losses	(43,000)
Fair Value	48,964,000
Realized gain (losses) on U.S. Treasury securities	$ 0

Fair Value of Financial Instr29

Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	$ 78,731
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	23,767
U.S. agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	6,000
U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	48,964
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	78,731	$ 98,454
Fair Value, Measurements, Recurring | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	23,767	36,414
Fair Value, Measurements, Recurring | U.S. agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	6,000
Fair Value, Measurements, Recurring | U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	48,964	62,040
Fair Value, Measurements, Recurring | LEVEL 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	72,731	98,454
Fair Value, Measurements, Recurring | LEVEL 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	23,767	36,414
Fair Value, Measurements, Recurring | LEVEL 1 | U.S. agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	0
Fair Value, Measurements, Recurring | LEVEL 1 | U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	48,964	62,040
Fair Value, Measurements, Recurring | LEVEL 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	6,000	0
Fair Value, Measurements, Recurring | LEVEL 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0	0
Fair Value, Measurements, Recurring | LEVEL 2 | U.S. agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	6,000
Fair Value, Measurements, Recurring | LEVEL 2 | U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	0	0
Fair Value, Measurements, Recurring | LEVEL 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0	0
Fair Value, Measurements, Recurring | LEVEL 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0	0
Fair Value, Measurements, Recurring | LEVEL 3 | U.S. agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	0
Fair Value, Measurements, Recurring | LEVEL 3 | U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities, fair value	$ 0	$ 0

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 0	$ 567
Work in process	541	0
Finished goods	83	40
Total inventory	$ 624	$ 607

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Research and development services	$ 4,179	$ 3,027
Legal and professional services	136	28
Employee compensation	1,406	1,880
Total accrued liabilities	$ 5,721	$ 4,935

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details)	Jan. 01, 2017USD ($)ft²	May 31, 2017USD ($)ft²	Jan. 31, 2017USD ($)	Oct. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jul. 31, 2015USD ($)	Jan. 31, 2015USD ($)ft²	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)
Other Commitments [Line Items]
Square feet of office and laboratory space (in square feet) | ft²	20,133						9,640
Operating lease, contract term (in years)	5 years
Operating lease, optional lease extension period (in years)	3 years						5 years
Operating lease, annual base rent	$ 1,100,000
Operating lease, annual increase in base rate (as a percent)	2.50%
Security deposit provided during the period			$ 200,000
Sublease area (in square feet) | ft²		5,048
Sub-lease term (in years)		3 years
Sublease minimum rental expense		$ 273,000
Sublease annual base rent increase (as a percent)		2.50%
Funds drawn on letter of credit								$ 0		$ 0
Research and development								10,863,000	$ 11,386,000	24,901,000	$ 21,956,000
Collaborative Arrangement | ZVex Product | Maximum
Other Commitments [Line Items]
Potential future milestone payments								7,700,000		7,700,000
Collaborative Arrangement | NanoPass Technologies LTD | Intradermal Delivery Device
Other Commitments [Line Items]
Collaborative arrangement, license fee					$ 500,000	$ 600,000
Research and development								0	$ 261,000	0	$ 522,000
Collaborative arrangement, non-refundable payment				$ 150,000
Collaborative Arrangement | NanoPass Technologies LTD | Intradermal Delivery Device | Maximum
Other Commitments [Line Items]
Potential future milestone payments				$ 8,800,000
Collaborative Arrangement | Infectious Disease Research Institute | GLA/SLA First Exclusive Product | Maximum
Other Commitments [Line Items]
Potential future milestone payments								2,300,000		2,300,000
Collaborative Arrangement | Infectious Disease Research Institute | GLA/SLA Subsequent Exclusive Products | Maximum
Other Commitments [Line Items]
Potential future milestone payments								1,300,000		1,300,000
Collaborative Arrangement | Infectious Disease Research Institute | GLA/SLA First Non-Exclusive Product | Maximum
Other Commitments [Line Items]
Potential future milestone payments								1,300,000		1,300,000
Collaborative Arrangement | Infectious Disease Research Institute | GLA/SLA Subsequent Non-Exclusive Products | Maximum
Other Commitments [Line Items]
Potential future milestone payments								$ 625,000		$ 625,000
Standby Letter of Credit
Other Commitments [Line Items]
Letter of credit provided as security deposit							$ 121,000

License and Collaboration Agr33

License and Collaboration Agreements - Narrative (Details)	1 Months Ended				3 Months Ended		6 Months Ended		8 Months Ended	12 Months Ended
	Oct. 31, 2016USD ($)payment	Dec. 31, 2015USD ($)	Nov. 30, 2015USD ($)	Aug. 31, 2014	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2009USD ($)	Dec. 31, 2016USD ($)	Oct. 31, 2010license_agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized							$ 0	$ 0
Research and development					$ 10,863,000	$ 11,386,000	24,901,000	21,956,000
Accounts receivable					495,000		495,000				$ 517,000
Sanofi Pasteur
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts receivable					428,000		428,000
Collaborative Arrangement, Product | GLAAS Discovery Platform | Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone agreement, notice period required for agreement termination (in months)				6 months
Milestone revenue recognized					0	0	0	0
Milestone receivables					160,000,000		160,000,000
Collaborative Arrangement, Product | GLA | MedImmune LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized					0	0	0	0
Number of license agreements | license_agreement												2
Collaborative Arrangement, Product | GLA | MedImmune LLC | Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables					62,900,000		62,900,000
Collaborative Arrangement, Product | GLA | MedImmune LLC | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables					72,500,000		72,500,000
Collaborative Arrangement, Product | GLA | Medicago Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized					0	0			$ 500,000
Milestone receivables					9,500,000		9,500,000
Collaborative Arrangement, Product | Herpes Simplex Virus Immune Therapy | Sanofi Pasteur | Collaboration Revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized					700,000	400,000	5,900,000	2,300,000
Collaborative Arrangement | TheraVectys SA
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development					0	0	0	0
Collaborative Arrangement | TheraVectys SA | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments	$ 5,750,000
Number of milestone payments waived (in payments) | payment	2
Collaborative Arrangement | GLAAS Discovery Platform | Infectious Disease Research Institute
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development			$ 250,000
Collaborative Arrangement | GLA | Infectious Disease Research Institute
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized					0	0	0	0
Collaborative Arrangement | First GLAAS Discovery Platform Product | Infectious Disease Research Institute
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments					250,000		250,000
Collaborative Arrangement | Subsequent GLAAS Discovery Platform Products | Infectious Disease Research Institute
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments					125,000		125,000
Collaborative Arrangement | GLA/SLA Product | Infectious Disease Research Institute
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development		$ 2,300,000
Collaborative Arrangement | GLA/SLA First Exclusive Product | Infectious Disease Research Institute | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments					2,300,000		2,300,000
Collaborative Arrangement | GLA/SLA Subsequent Exclusive Products | Infectious Disease Research Institute | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments					1,300,000		1,300,000
Collaborative Arrangement | GLA/SLA First Non-Exclusive Product | Infectious Disease Research Institute | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments					1,300,000		1,300,000
Collaborative Arrangement | GLA/SLA Subsequent Non-Exclusive Products | Infectious Disease Research Institute | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments					625,000		625,000
Collaborative Arrangement | Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies | CalTech
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized					100,000	$ 0	100,000	$ 0
Annual minimum royalty payments										$ 25,000
Collaborative Arrangement | Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies | CalTech | Common Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Value of common stock issued for license										$ 25,000
Collaborative Arrangement | Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies | CalTech | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments					$ 1,500,000		$ 1,500,000

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($) $ in Thousands	Jan. 01, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Equity [Abstract]
Preferred shares issued (in shares)		0		0
Preferred shares outstanding (in shares)		0		0
Common shares outstanding (in shares)		25,590,065		25,413,055
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock based compensation expense		$ 14,200
Weighted average recognition period for stock-based compensation expense (in years)		2 years 3 months 10 days
Intrinsic value of stock options exercised		$ 639	$ 34
2014 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual additional shares authorized (as a percent)		4.00%
Increase in authorized shares (in shares)	1,016,522
Common stock authorized (in shares)		3,953,577
2014 Employee Stock Purchase Plan | Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual additional shares authorized (as a percent)		1.00%
Increase in authorized shares (in shares)		200,000
Common stock authorized (in shares)		484,822

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details) - shares	Jun. 30, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	5,765,498	4,925,986
Employee Stock Purchase Plan
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	484,822	503,620
Options
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	4,142,900	3,590,393
Restricted Stock Units
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	297,025	107,250
Future Stock Grants
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)	840,751	724,723

Stockholders' Equity - Schedu36

Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units	6 Months Ended
	Jun. 30, 2017$ / sharesshares
SHARES
Outstanding, beginning balance (in shares) | shares	107,250
Granted (unaudited) (in shares) | shares	224,540
Vested (unaudited) (in shares) | shares	(26,802)
Forfeited (unaudited) (in shares) | shares	(7,963)
Outstanding, ending balance (unaudited) (in shares) | shares	297,025
WEIGHTED AVERAGE GRANT DATE FAIR VALUE (per share)
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 19.39
Granted (unaudited) (in dollars per share) | $ / shares	5.60
Vested (unaudited) (in dollars per share) | $ / shares	19.39
Forfeited (unaudited) (in dollars per share) | $ / shares	11.12
Outstanding, ending balance (unaudited) (in dollars per share) | $ / shares	$ 9.19

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
OPTIONS OUTSTANDING
Options outstanding, beginning balance (in shares)	3,590,393
Options granted (unaudited) (in shares)	819,801
Options exercised (unaudited) (in shares)	(131,410)
Options expired (unaudited) (in shares)	(48,478)
Options forfeited (unaudited) (in shares)	(87,406)
Options outstanding, ending balance (unaudited) (in shares)	4,142,900	3,590,393
Exercisable options as of June 30, 2017 (unaudited) (in shares)	2,168,589
WEIGHTED- AVERAGE EXERCISE PRICE
Options outstanding, beginning balance (in dollars per share)	$ 12.13
Options granted (unaudited) (in dollars per share)	5.93
Options exercised (unaudited) (in dollars per share)	1.24
Options expired (unaudited) (in dollars per share)	18.82
Options forfeited (unaudited) (in dollars per share)	14.13
Options outstanding, ending balance (unaudited) (in dollars per share)	11.13	$ 12.13
Exercisable options as of June 30, 2017 (unaudited) (in dollars per share)	$ 10.63
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining contract term for outstanding options (in years)	7 years 6 months 21 days	7 years 3 months 29 days
Weighted average remaining contract term for exercisable options as of June 30, 2017 (unaudited) (in years)	6 years 5 months 1 day
Aggregate intrinsic value	$ 13,063
Aggregate intrinsic value of exercisable options as of June 30, 2017 (unaudited)	$ 8,829

Stockholders' Equity - Schedu38

Stockholders' Equity - Schedule of Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 2,205	$ 2,246	$ 4,452	$ 4,581
Employee | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	904	927	1,837	1,936
Employee | General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,242	1,258	2,522	2,555
Non-Employee | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	34	35	57	37
Non-Employee | General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 25	$ 26	$ 36	$ 53

Stockholders' Equity - Schedu39

Stockholders' Equity - Schedule of Fair Value of Stock Options Granted to Employees (Details) - Options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average estimated fair value (in dollars per share)	$ 4.86	$ 8.64	$ 3.93	$ 12.48
Expected term of options (in years)	6 years 29 days
Expected stock price volatility (as a percent)	80.00%
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (as a percent)	1.86%	1.19%	1.86%	1.19%
Expected term of options (in years)		5 years 10 months 6 days	5 years 6 months	5 years 6 months
Expected stock price volatility (as a percent)		78.00%	80.00%	77.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (as a percent)	1.98%	1.49%	2.09%	1.84%
Expected term of options (in years)		6 years 29 days	6 years 29 days	6 years 29 days
Expected stock price volatility (as a percent)		80.00%	82.00%	80.00%

Legal Proceedings (Details)

Legal Proceedings (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2017	Oct. 17, 2016
Collaborative Arrangement | TheraVectys SA
Loss Contingencies [Line Items]
Settlement agreement allocated to license agreement	$ 1,400,000		$ 1,400,000
TheraVectys SA v. Immune Design Corp. | Settled Litigation
Loss Contingencies [Line Items]
Settlement agreement, escrow deposit			6,000,000
Settlement agreement, contingent escrow payment			1,250,000
Settlement agreement, contingent escrow deposit, capital funding threshold			$ 25,000,000
Release of escrow deposit due to granting of sublicense (as a percent)			50.00%
Release of escrow deposit due to final resolution of EPO proceedings (as a percent)			50.00%
Escrow payment disbursed during period		$ 0
Litigation settlement and license agreement fees			$ 7,250,000
Litigation settlement			$ 5,850,000
Settlement agreement for dismissal of litigation	$ 5,850,000

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event	Jul. 03, 2017USD ($)
Subsequent Event [Line Items]
Value of shares authorized under purchase agreement	$ 50,000,000
Commission, percent of gross sales proceeds	3.00%